Canna_Business
9 minutes ago
The potential reclassification of cannabis by the DEA, removing it from the schedule-1 drugs list, could significantly impact both medical research and patient access. By allowing the FDA to thoroughly study cannabis for its medical applications, we could see more evidence-based treatments emerge. A